Extended Data Fig. 5: Safety of NanoFLUID for in vivo transfection.
From: A battery-free nanofluidic intracellular delivery patch for internal organs
a, Representative IHC staining for IL-6, IL-10, and TNF-α in the treated (NanoFLUID implantation or LPS exposure) or untreated mammary tissues. Red arrowheads indicate positive foci of the cytokines. b, Statistical results of total positive foci number in the IHC sections of each group. c, Photographs and H&E staining of the treated or untreated mammary glands after 3 weeks. Indications in the enlarged view show immune cell infiltration associated with LPS exposure. d, Changes in water consumption, food intake, and body weight of mice with NanoFLUID implantation during the 3-week experiment in comparison to untreated mice or mice undergoing sham surgery. e, Open field test results of the total travelling distance, time spent in the center of the arena, and run speed of each group of mice. f, Blood test results including complete blood count (WBC, RBC, HGB, PLT), biochemical parameters (ALP, GLU, TP, ALB, CHOL, TRIG), and liver function damage indicators (ALT, AST) of mice in each group over the 3 weeks. Results are mean ± s.d. of n = 5 (b, d-f) mice per group. p values were calculated by one-way ANOVA (d-f) with Tukey’s post hoc test (b). ns (not significant) represents p ≥ 0.05.
